Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of
clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary …

Pulmonary Langerhans cell (LC) histiocytosis (PLCH) has unknown cause and is a rare
neoplastic disorder characterized by the infiltration of lungs and various organs by bone …

The mitogen-activated protein kinase (MAPK) pathway is a key driver in many histiocytic
disorders, including Langerhans cell histiocytosis (LCH) and Erdheim–Chester disease …

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers
of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders …

The standard treatment for Langerhans cell histiocytosis (LCH) is chemotherapy, although
the failure rates are high. Since MAP-kinase activating mutations are found in most cases …

Advances in the treatment of Langerhans cell histiocytosis (LCH) have resulted in a growing
survivor population. There is a lack of data on long-term outcomes among adults with LCH …

With the advent of targeted therapeutics in Langerhans cell histiocytosis (LCH), there is a
growing survivor population that might be at risk for late mortality from non-LCH causes …

GG, MH and JPA collected the data. GG wrote the first manuscript draft with assistance from
JPAJRY, TGC, CCH, AP, DJI, RV, KLR, JHR, CJD-P., WOT, MJK, NNB, MVS and RSG …

Most children with high-risk Langerhans cell histiocytosis (LCH) have BRAF V600E
mutation. BRAF V600E alleles are detectable in myeloid mononuclear cells at diagnosis but …

The parasellar region is the anatomical area around the sella turcica that represents a
crucial crossroad for important adjacent structures. Several distinct tumors can primarily …